By Dr. Jaisingh Rajput, MD  Sleep is essential for heart health, but millions of Americans unknowingly suffer from sleep ...

Results were announced from a phase 3 trial evaluating solriamfetol for major depressive disorder with/without severe excessive daytime sleepiness.

Centessa Pharmaceuticals plc shifts focus to ORX750 for sleep disorders after discontinuing SerpinPC. Click here to find out ...

Among patients with obstructive sleep apnea using CPAP, pitolisant given at 20 mg and 40 mg reduces excessive daytime sleepiness.

Adaptive deep brain stimulation has virtually eliminated the most debilitating motor symptoms for some Parkinson’s patients ...

A massive new study suggests bedtime screen time could be seriously damaging your sleep. Researchers found that even one ...

Axsome Therapeutics AXSM announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the ...

Among patients with obstructive sleep apnea and excessive daytime sleepiness-related cognitive impairment, 2-week solriamfetol led to cognitive function improvement on three tests/scales, according to ...

Axsome Therapeutics, Inc. has announced the topline results of the Paradigm Phase 3 proof-of-concept trial of Solriamfetol in major depressive disorder (MDD) with and without excessive daytime ...

A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...

Axsome Therapeutics posted mixed results for its experimental depression treatment on Tuesday, leading Axsome stock to dive.